When it comes to how high they price their products, drug companies want the public to ignore what they spend on marketing and the tax breaks they get for direct-to-consumer advertising. Instead of simply acknowledging their pricing strategies, drug companies and their lobbyists have launched a finger-pointing campaign at pharmacy benefit managers (PBMs). This isn’t […]
This content is only available to members of the CSBJ. To gain access, you'll need to sign in or purchase Digital, Digital Partnership, Silver Membership, Print & Digital, Print, Digital and The Transcript or Digital Monthly If you're already a member, sign in here.